Discontinuation report DALACIN C 300 MG
Report ID | 241493 |
Drug Identification Number | 02182866 |
Brand name | DALACIN C 300 MG |
Common or Proper name | DALACIN C 300 MG |
Company Name | PFIZER CANADA ULC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | CLINDAMYCIN |
Strength(s) | 300MG |
Dosage form(s) | CAPSULE |
Route of administration | ORAL ORAL |
Packaging size | 100 BTL |
ATC code | J01FF |
ATC description | MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | |
Actual discontinuation date | 2024-10-29 |
Remaining supply date | |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2024-10-30 | English | Compare |
v2 | 2024-10-29 | French | Compare |
v1 | 2024-10-29 | English | Compare |
Showing 1 to 3 of 3